Approval · Notice of Compliance 6645 · 2005
MACUGEN: Notice of Compliance 6645
Issued May 2, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 6645
- Date
- May 2, 2005
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Anti-vascular endothelium growth factor (vegf165 inhibitor) for age-related macular degeneration
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MACUGEN | 02267225 | Cancelled Post Market |
Medicinal ingredients
- PEGAPTANIB 0.3 MG per 90MCL